Manufacturer record
Swift Life Sciences Pvt. Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
6 batches manufactured by Swift Life Sciences Pvt. Ltd (Uttarakhand) were declared Not of Standard Quality between July 2024 and September 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: SLTF26030, Buprenorphine and Naloxone sublingual Tablets I.P. 2mg+ 0.5mg (exp May 2028). SDTL, Punjab (state lab) found it not of standard quality: 1. The content of Buprenorphine found to be 1.74 mg per tablet (87%) against labelled claim of 2.0 mg per tablet. 2. The content of Naloxone. Listed in the September 2026 alert.
Records by type
6 records linked to Swift Life Sciences Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Buprenorphine and Naloxone sublingual Tablets I.P. 2mg+ 0.5mg | Batch SLTF26030Mfg Jun 2026 · Exp May 2028 | 1. The content of Buprenorphine found to be 1.74 mg per tablet (87%) against labelled claim of 2.0 mg per tablet. 2. The content of Naloxone found to be 0.432 mg per tablet (86.40%) against labelled claim of 0.5 mg per tablet.Labelling | SDTL, PunjabState lab | Sep 2026 |
| Buprenorphine HCI and Naloxone Sublingula Tablets I.P. | Batch SLTE26026Mfg May 2026 · Exp Apr 2028 | The content of Buprenorphine found to be 0.451 mg per tablet (112.75%) against labelled claim of 0.4 mg per tabletLabelling | SDTL, PunjabState lab | Sep 2026 |
| DENOCK N | Batch SLTC24010Mfg Mar 2024 · Exp Feb 2026 | The content of Naloxone found to be 0.1169 mg per tablet (116.9%) labelled claim of 0.1mg per tabletLabelling | SDTL, PunjabState lab | Oct 2025 |
| Buprenorphine and Naloxone Sublingual Tablets I.P. 2mg+0.5mg ((Akknck-N)) | Batch SLTG25022Mfg Jul 2025 · Exp Jun 2027 | ContentOther | SDTL, PunjabState lab | Oct 2025 |
| BUPERA N LITE | Batch SLTE25016Mfg May 2025 · Exp Apr 2027 | The content of Naloxone found to be 0.112mg/tablet (112%) against labelled claim of 0.1mg/tablet.Labelling | SDTL, PunjabState lab | Oct 2025 |
| Oxalobacter, Lactobacillus & Bifidobacteriu m with FOS Capsules (OXASPUR) | Batch RHCE23001Mfg May 2023 · Exp Oct 2024 | Assay of Oxalobacter Species & Bifidobacteriu m BifidumAssay | CDL KolkataCDSCO lab | Jul 2024 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.